Amgen Inc (AMGN)

NASDAQ
में मुद्रा USD
अस्वीकरण
218.07
+3.80
(+1.77%)
बंद
218.11
+0.04
(+0.02%)
समय के बाद
रियल टाइम डेटा
दिन की रेंज
212.02
218.76
52 सप्ताह रेंज
211.71
296.67
वॉल्यूम
3,594,127
पिछला बंद
214.27
खुला
213.75
दिन की रेंज
212.02-218.76
52 सप्ताह रेंज
211.71-296.67
वॉल्यूम
3,594,127
औसत वॉल्यूम (3एम)
2,344,231
1- वर्ष बदलाव
-12.23%
बकाया शेयर
534,326,594
विश्लेषक
तकनीकी
मजबूत विक्रय
बेचना
तटस्थ
खरीदें
मजबूत खरीद
मजबूत विक्रय

लोग इसे भी देखते हैं

77.89
GILD
+2.20%
136.87
ABBV
+2.57%
115.62
QCOM
-0.18%

Amgen Inc समाचार

Amgen Inc विश्लेषण

Amgen Inc कंपनी प्रोफाइल

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

क्षेत्र
हेल्थकेयर
कर्मचारी
24200